• Northwest Biotherapeutics moved to counter market rumors of an MHRA rejection of its UK marketing application for DCVax-L in glioblastoma.
• MHRA confirmation: the application remains in initial regulatory review, not refused, withdrawn, or appealed.
• Process continues toward a first regulatory decision; interactions with the MHRA described as constructive.
• Company rejected the rumors, linking them to alleged stock manipulation following release of encouraging Phase 3 trial data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Northwest Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-084743), on July 20, 2026, and is solely responsible for the information contained therein.